We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Dosage of Metformin on Menstruation and Lipid Profile in Women With Polycystic Ovary Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01474967
First Posted: November 18, 2011
Last Update Posted: November 21, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hamidreza Mahboobi, Hormozgan University of Medical Sciences
  Purpose
Polycystic ovarian syndrome (PCOS) is the most common cause of anovulatory infertility and causes menstrual disruption in 6.6-6.8% of women in reproductive age and is characterized by insulin resistance, hyperinsulinemia, hyperandrogenism and anovulation. The gaol of this study was to assess the effects of metformin on menstrual disorders and lipid profile in women with PCOS in bandarabbas.

Condition Intervention
Polycystic Ovary Syndrome Drug: Metformin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Dosage of Metformin on Menstruation and Lipid Profile in Women With Polycystic Ovary Syndrome

Resource links provided by NLM:


Further study details as provided by Hamidreza Mahboobi, Hormozgan University of Medical Sciences:

Primary Outcome Measures:
  • Lipid profile [ Time Frame: 6 month ]
    The serum levels of Cholesterol, LDL, HDL and Triglyceride were measured before and after of treatment in both groups.


Secondary Outcome Measures:
  • Hormone levels [ Time Frame: 6 month ]
    LH, FSH, Testosterone


Enrollment: 50
Study Start Date: February 2010
Study Completion Date: February 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lower metformin dose group
500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
Drug: Metformin
500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
Other Name: metformex
Active Comparator: Higher metformin dose group
500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
Drug: Metformin
500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
Other Name: metformex

Detailed Description:

Poly cystic ovarian syndrome (PCOS) is a common hormonal disorder in women that affecting of 6.6-6.8% of women o f reproductive age. PCOS associated with a broad range of clinical, hormonal and metabolic disorders consist of hirsutism, Obesity, Acne and elevated male hormones, anovulatory cycles, dyslipidemia and infertility.

Metformin is an oral hyperglycemic agent witch by decrease insulin resistance and improving serum glucose level in diabetic patients and anovulatory cyle in women with PCOS. The goal of this study is to evaluate the efficacy of different dosage of metformin on menstruation and lipid profile in women with PCOS in banda-abbas.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women with PCOS

Exclusion Criteria:

  • avoiding to participate in the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01474967


Locations
Iran, Islamic Republic of
Hormozgan University of Medical Sciences (HUMS)
Bandarabbas, Hormozgan, Iran, Islamic Republic of, 791451692
Sponsors and Collaborators
Hormozgan University of Medical Sciences
Investigators
Principal Investigator: Nazanin Abdi, resident Hormozgan University of Medical Sciences (HUMS)
  More Information

Responsible Party: Hamidreza Mahboobi, Resident, Hormozgan University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01474967     History of Changes
Other Study ID Numbers: Metformin in PCOS
First Submitted: November 16, 2011
First Posted: November 18, 2011
Last Update Posted: November 21, 2011
Last Verified: November 2011

Keywords provided by Hamidreza Mahboobi, Hormozgan University of Medical Sciences:
polycystic ovary syndrome
lipid profile
metformin

Additional relevant MeSH terms:
Syndrome
Polycystic Ovary Syndrome
Disease
Pathologic Processes
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs